Raj Gandesha

Pfizer, 2014–ongoing
Raj is representing Pfizer in federal class action antitrust litigations with respect to Celebrex, accusing the company of delaying entry of generic competition for Celebrex through alleged fraud on the US patent office and sham patent litigation. In re Celebrex Antitrust Litigation (E.D. Va.).

Pfizer, 2011–ongoing
Raj is representing Pfizer in federal consolidated class action antitrust litigations and a state court action brought by the West Virginia Attorney General with respect to Lipitor, which accused the company of delaying entry of generic competition for Lipitor through alleged fraud on the US patent office and sham patent litigation, a sham FDA citizen petition and a reverse payment settlement agreement. In re Lipitor Antitrust Litigation (D.N.J.); State of West Virginia v. Pfizer, Inc., et al. (Cir. Ct., Mason Cty., W.V.).

Pfizer, 2011–ongoing
Raj is representing Pfizer in federal class action antitrust litigations with respect to Effexor XR, accusing the company of delaying entry of generic competition for Effexor XR through alleged fraud on the US patent office, sham patent litigation and a reverse payment settlement agreement. In re Effexor XR Antitrust Litigation (D.N.J.).

Sandoz, 2009–present
Raj has represented Sandoz in multiple state and federal actions alleging false claims act, common law fraud and consumer protection claims based on allegations that drug manufacturers reported inaccurate pricing benchmarks that allegedly caused state Medicaid agencies to overpay for prescription drugs provided to Medicaid beneficiaries.